Bill
HF 2275
HF 2275 would modify Minnesota insulin manufacturer registration fees, including how much, how calculated, when paid, exemptions, and enforcement.
Title: Summary of HF 2275 (2025-2026) – Minnesota insulin manufacturer registration fee provisions modified
Purpose and intent
- HF 2275 proposes changes to the registration fee requirements for insulin manufacturers operating in Minnesota. The bill aims to modify how fees are assessed, collected, and/or used, with potential impacts on manufacturers and the state’s administration of insulin-related regulation.
- The sponsor (House Co-sponsor: Mike Howard) indicates an intent to adjust financial obligations or reporting related to insulin manufacturers, though the bill’s text would specify the exact nature of the modifications.
Key provisions and changes (highlights)
- Registration fee framework: The bill modifies the structure of registration fees for insulin manufacturers. This could involve changes to:
- Fee amount or rate
- Fee calculation methodology (e.g., based on production volume, market share, or number of products)
- Frequency of payment (annual, biennial, etc.)
- Fee exemptions or thresholds: The bill may create, modify, or remove exemptions, waivers, or threshold-based relief for small manufacturers, startups, or certain types of insulin products.
- Administrative processes: The bill could alter:
- Application and renewal procedures for registration
- Documentation required for compliance
- Enforcement provisions or penalties for non-compliance
- Allocation or earmarking of fee revenue (e.g., to the Department of Health, insulin safety programs, or regulatory administration)
- Scope and applicability: The measure likely clarifies which entities are subject to the insulin registration fees (e.g., manufacturers, importers, or distributors) and may specify geographic applicability within Minnesota.
- Dates and transition: If applicable, the bill may include effective dates, transition rules for existing registrations, and phase-in periods for new fee structures.
Persons and entities affected
- Insulin manufacturers and importers selling or distributing insulin in Minnesota
- Potentially other entities involved in the insulin supply chain if they are required to register
- State regulatory agencies responsible for health/commerce oversight and fee collection
- Consumers indirectly, through the potential impact on insulin pricing or regulatory resources
Procedural and timeline aspects
- Introduction and referral: HF 2275 was introduced and referred to the Health Finance and Policy committee on March 13, 2025.
- Next steps: The bill will be subject to committee hearings, potential amendments, and votes in the House. If advanced, it could proceed to the Senate and require committee consideration and a final passage vote, followed by any required signature or veto process and potential implementation dates.
- Effective date: The bill will specify an effective date for any new or revised registration fee provisions, including any transition period.
Notes and caveats
- The summary above reflects the bill’s general stated category (modifications to insulin manufacturer registration fee provisions). For precise language, including exact fee amounts, calculation methods, exemptions, penalties, and effective dates, the bill text and any fiscal notes should be consulted.
- Status may change with committee action, amendments, or floor votes.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
